Targeting the tumor microenvironment: The protumor effects of IL-17 related to cancer type

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Fabre, Joseph ^a,b,c   Giustiniani, Jerome ^a,b   Garbar, Christian ^a,b   Antonicelli, Frank ^b   Merrouche, Yacine ^a,b   Bensussan, Armand ^d,e,f   Bagot, Martine ^d,e   Al Dacak, Reem ^e  

^a INSTITUT JEAN GODINOT   (France)

^b DERM I C ^*  (France)

^c HENRI MONDOR HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f OREGA Biotech   (France)

Author keywords

Cancer; Immunotherapy; Interleukin 17 (IL 17); Tumor microenvironment

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SYNAPTOBREVIN; TRANSCRIPTION FACTOR FOXP3;

BRAIN TUMOR; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COLON CANCER; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; LUNG CANCER; NEOPLASM; NONHUMAN; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; REVIEW; SARCOMA; SKIN CANCER; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; UTERINE CERVIX CANCER; ANIMAL; CLASSIFICATION; GENETICS; HELPER CELL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-17; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR MICROENVIRONMENT;

EID: 85016121358     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091433     Document Type: Review

References (96)

1. Joyce, J.A.; Fearon, D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348, 74-80. [CrossRef] [PubMed]
2. He, D.; Li, H.; Yusuf, N.; Elmets, C.A.; Li, J.; Mountz, J.D.; Xu, H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 2010, 184, 2281-2288. [CrossRef] [PubMed]
3. DelaCruz-Merino, L.; Barco-Sanchez, A.; Henao Carrasco, F.; Nogales Fernandez, E.; Vallejo Benitez, A.; Brugal Molina J.; Martinez Peinado A.; Grueso Lopez, A.; Ruiz Borrego, M.; Codes Manuel de Villena M. et al. New insights into the role of the immune microenvironment in breast carcinoma. Clin. Dev. Immunol. 2013, 2013, 785317-785328. [CrossRef] [PubMed]
4. Quail, D.F.; Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19, 1423-1437. [CrossRef] [PubMed]
5. Quail, D.F.; Bowman, R.L.; Akkari, L.; Quick, M.L.; Schuhmacher, A.J.; Huse, J.T.; Holland, E.C.; Sutton, J.C.; Joyce, J.A. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 2016. [CrossRef] [PubMed]
6. Bowman, R.L.; Joyce, J.A. Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma. Immunotherapy 2014, 6, 663-666. [CrossRef] [PubMed]
7. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148. [CrossRef] [PubMed]
8. Beyer, M.; Schultze, J.L. Regulatory T cells in cancer. Blood 2006, 108, 804-811. [CrossRef] [PubMed]
9. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998. [CrossRef] [PubMed]
10. Mantovani, A.; Romero, P.; Palucka, A.K.; Marincola, F.M. Tumour immunity: Effector response to tumour and role of the microenvironment. Lancet 2008, 371, 771-783. [CrossRef]
11. Yao, Z.; Painter, S.L.; Fanslow, W.C.; Ulrich, D.; Macduff, B.M.; Spriggs, M.K.; Armitage, R.J. Human IL-17: A novel cytokine derived from T cells. J. Immunol. 1995, 155, 5483-5486. [PubMed]
12. Maniati, E.; Soper, R.; Hagemann, T. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 2010, 29, 5653-5662. [CrossRef] [PubMed]
13. Novitskiy, S.V.; Pickup, M.W.; Gorska, A.E.; Owens, P.; Chytil, A.; Aakre, M.;Wu, H.; Shyr, Y.; Moses, H.L. TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov. 2011, 1, 430-441. [CrossRef] [PubMed]
14. West, N.R.; Kost, S.E.; Martin, S.D.; Milne, K.; Deleeuw, R.J.; Nelson, B.H.; Watson, P.H. Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 2013, 108, 155-162. [CrossRef] [PubMed]
15. Su, X.; Ye, J.; Hsueh, E.C.; Zhang, Y.; Hoft, D.F.; Peng, G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 2010, 184, 1630-1641. [CrossRef] [PubMed]
16. Miyashita, M.; Sasano, H.; Tamaki, K.; Hirakawa, H.; Takahashi, Y.; Nakagawa, S.; Watanabe, G.; Tada, H.; Suzuki, A.; Ohuchi, N. et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: A retrospective multicenter study. Breast Cancer Res. 2015, 17, 124-137. [CrossRef] [PubMed]
17. Gu, C.; Wu, L.; Li, X. IL-17 family: Cytokines, receptors and signaling. Cytokine 2013, 64, 477-485. [CrossRef] [PubMed]
18. Tesmer, L.A.; Lundy, S.K.; Sarkar, S.; Fox, D.A. Th17 cells in human disease. Immunol. Rev. 2008, 223, 87-113. [CrossRef] [PubMed]
19. Yang, X.O.; Pappu, B.P.; Nurieva, R.; Akimzhanov, A.; Kang, H.S.; Chung, Y.; Ma, L.; Shah, B.; Panopoulos, A.D.; Schluns, K.S. et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORϒ and ROR. Immunity 2008, 28, 29-39. [CrossRef] [PubMed]
20. Zhou, L.; Ivanov, I.I.; Spolski, R.; Min, R.; Shenderov, K.; Egawa, T.; Levy, D.E.; Leonard, W.J.; Littman, D.R. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007, 8, 967-974. [CrossRef] [PubMed]
21. Cua, D.J.; Sherlock, J.; Chen, Y.; Murphy, C.A.; Joyce, B.; Seymour, B.; Lucian, L.; To, W.; Kwan, S.; Churakova, T. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421, 744-748. [CrossRef] [PubMed]
22. Wilson, N.J.; Boniface, K.; Chan, J.R.; McKenzie, B.S.; Blumenschein, W.M.; Mattson, J.D.; Basham, B.; Smith, K.; Chen, T.; Morel, F. et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007, 8, 950-957. [CrossRef] [PubMed]
23. Yang, X.O.; Chang, S.H.; Park, H.; Nurieva, R.; Shah, B.; Acero, L.; Wang, Y.H.; Schluns, K.S.; Broaddus, R.R.; Zhu, Z. et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 2008, 205, 1063-1075. [CrossRef] [PubMed]
24. Van Beelen, A.J.; Zelinkova, Z.; Taanman-Kueter, E.W.; Muller, F.J.; Hommes, D.W.; Zaat, S.A.; Kapsenberg, M.L.; de Jong, E.C. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007, 27, 660-669. [CrossRef] [PubMed]
25. Kryczek, I.; Wei, S.; Gong, W.; Shu, X.; Szeliga, W.; Vatan, L.; Chen, L.; Wang, G.; Zou, W. Cutting edge: IFN enables APC to promote memory Th17 and abate Th1 cell development. J. Immunol. 2008, 181, 5842-5846. [CrossRef] [PubMed]
26. Martin-Orozco, N.; Muranski, P.; Chung, Y.; Yang, X.O.; Yamazaki, T.; Lu, S.; Hwu, P.; Restifo, N.P.; Overwijk, W.W.; Dong, C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31, 787-798. [CrossRef] [PubMed]
27. Kryczek, I.; Banerjee, M.; Cheng, P.; Vatan, L.; Szeliga, W.; Wei, S.; Huang, E.; Finlayson, E.; Simeone, D.; Welling, T.H. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114, 1141-1149. [CrossRef] [PubMed]
28. Ghadjar, P.; Rubie, C.; Aebersold, D.M.; Keilholz, U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int. J. Cancer 2009, 125, 741-745. [CrossRef] [PubMed]
29. Muranski, P.; Boni, A.; Antony, P.A.; Cassard, L.; Irvine, K.R.; Kaiser, A.; Paulos, C.M.; Palmer, D.C.; Touloukian, C.E.; Ptak, K. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112, 362-373. [CrossRef] [PubMed]
30. Kryczek, I.; Liu, R.; Wang, G.; Wu, K.; Shu, X.; Szeliga, W.; Vatan, L.; Finlayson, E.; Huang, E.; Simeone, D. et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009, 69, 3995-4000. [CrossRef] [PubMed]
31. Rouvier, E.; Luciani, M.F.; Mattei, M.G.; Denizot, F.; Golstein, P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993, 150, 5445-5456. [PubMed]
32. Kolls, J.K.; Linden, A. Interleukin-17 family members and inflammation. Immunity 2004, 21, 467-476. [CrossRef] [PubMed]
33. Moseley, T.A.; Haudenschild, D.R.; Rose, L.; Reddi, A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003, 14, 155-174. [CrossRef]
34. Xu, S.; Cao, X. Interleukin-17 and its expanding biological functions. Cell. Mol. Immunol. 2010, 7, 164-174. [CrossRef] [PubMed]
35. Jin, W.; Dong, C. IL-17 cytokines in immunity and inflammation. Emerg. Microbes Infect. 2013, 2, 60-65. [CrossRef] [PubMed]
36. Song, X.; Qian, Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013, 62, 175-182. [CrossRef] [PubMed]
37. Chen, Z.; O’Shea, J.J. Regulation of IL-17 production in human lymphocytes. Cytokine 2008, 41, 71-78. [CrossRef] [PubMed]
38. Kirkham, B.W.; Kavanaugh, A.; Reich, K. Interleukin-17A: A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 2014, 141, 133-142. [CrossRef] [PubMed]
39. Toy, D.; Kugler, D.; Wolfson, M.; Vanden Bos, T.; Gurgel, J.; Derry, J.; Tocker, J.; Peschon, J. Cutting edge: Interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 2006, 177, 36-39. [CrossRef] [PubMed]
40. Rickel, E.A.; Siegel, L.A.; Yoon, B.R.P.; Rottman, J.B.; Kugler, D.G.; Swart, D.A.; Anders, P.M.; Tocker, J.E.; Comeau, M.R.; Budelsky, A.L. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 2008, 181, 4299-4310. [CrossRef] [PubMed]
41. Shalom-Barak, T.; Quach, J.; Lotz, M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J. Biol. Chem. 1998, 273, 27467-27473. [CrossRef] [PubMed]
42. Chang, S.H.; Park, H.; Dong, C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J. Biol. Chem. 2006, 281, 35603-35607. [CrossRef] [PubMed]
43. Zhang, B.; Liu, C.; Qian, W.; Han, Y.; Li, X.; Deng, J. Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved α-helix for Act1 binding and IL-17 signaling. Acta Crystallogr. D Biol. Crystallogr. 2014, 70, 1476-1483. [CrossRef] [PubMed]
44. Sun, F.; Qu, Z.; Xiao, Y.; Zhou, J.; Burns, T.F.; Stabile, L.P.; Siegfried, J.M.; Xiao, G. NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function. Oncogene 2016, 35, 2299-2310. [CrossRef] [PubMed]
45. Fabre, J.; Giustinniani, J.; Antonicelli, F.; Merrouche, Y.; Bagot, M.; Bensussan, A. A focus on IL-17 targeting treatments in psoriasis. J. Dermatol. Res. 2016, 2, 1-5.
46. Haudenschild, D.; Moseley, T.; Rose, L.; Reddi, A.H. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J. Biol. Chem. 2002, 277, 4309-4316. [CrossRef] [PubMed]
47. Steiner, G.E.; Newman, M.E.; Paikl, D.; Stix, U.; Memaran-Dagda, N.; Lee, C.; Marberger, M.J. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56, 171-182. [CrossRef] [PubMed]
48. Sfanos, K.S.; Bruno, T.C.; Maris, C.H.; Xu, L.; Thoburn, C.J.; DeMarzo, A.M.; Meeker, A.K.; Isaacs, W.B.; Drake, C.G. Phenotypic analysis of prostate-infiltrating lymphocytes reveals Th17 and Treg skewing. Clin. Cancer Res. 2008, 14, 3254-3261. [CrossRef] [PubMed]
49. Zhang, B.; Rong, G.; Wei, H.; Zhang, M.; Bi, J.; Ma, L.; Xue, X.; Wei, G.; Liu, X.; Fang, G. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 2008, 374, 533-537. [CrossRef] [PubMed]
50. Derhovanessian, E.; Adams, V.; Hahnel, K.; Groeger, A.; Pandha, H.; Ward, S.; Pawelec, G. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 2009, 125, 1372-1379. [CrossRef] [PubMed]
51. Horlock, C.; Stott, B.; Dyson, P.J.; Morishita, M.; Coombes, R.C.; Savage, P.; Stebbing, J. The effects of trastuzumab on the CD4+ CD25+ FOXP3+ and CD4+ IL17A+ T-cell axis in patients with breast cancer. Br. J. Cancer 2009, 100, 1061-1067. [CrossRef] [PubMed]
52. Qian, X.; Chen, H.; Wu, X.; Hu, L.; Huang, Q.; Jin, Y. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine 2015. [CrossRef] [PubMed]
53. Tartour, E.; Fossiez, F.; Joyeux, I.; Galinha, A.; Gey, A.; Claret, E.; Sastre-Garau, X.; Couturier, J.; Mosseri, V.; Vives, V. et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999, 59, 3698-3704. [PubMed]
54. Punt, S.; Fleuren, G.J.; Kritikou, E.; Lubberts, E.; Trimbos, J.B.; Jordanova, E.S.; Gorter, A. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. Oncoimmunology 2015, 4, e984539. [CrossRef] [PubMed]
55. Lyon, D.E.; McCain, N.L.; Walter, J.; Schubert, C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs. Res. 2008, 57, 51-58. [CrossRef] [PubMed]
56. Zhu, X.; Mulcahy, L.A.; Mohammed, R.A.; Lee, A.H.; Franks, H.A.; Kilpatrick, L.; Yilmazer, A.; Paish, E.C.; Ellis, I.O.; Patel, P.M. et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008, 10, 95-106. [CrossRef] [PubMed]
57. Du, J.W.; Xu, K.Y.; Fang, L.Y.; Qi, X.L. Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol. Med. Rep. 2012, 6, 1099-1102. [CrossRef] [PubMed]
58. Furuta, S.; Jeng, Y.M.; Zhou, L.; Huang, L.; Kuhn, I.; Bissell, M.J.; Lee, W.H. IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci. Transl. Med. 2011. [CrossRef] [PubMed]
59. Kim, G.; Khanal, P.; Lim, S.C.; Yun, H.J.; Ahn, S.G.; Ki, S.H.; Choi, H.S. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. Carcinogenesis 2013, 34, 341-350. [CrossRef] [PubMed]
60. Cochaud, S.; Giustiniani, J.; Thomas, C.; Laprevotte, E.; Garbar, C.; Savoye, A.M.; Cure, H.; Mascaux, C.; Alberici, G.; Bonnefoy, N. et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci. Rep. 2013, 3, 3456-3466. [CrossRef] [PubMed]
61. Mombelli, S.; Cochaud, S.; Merrouche, Y.; Garbar, C.; Antonicelli, F.; Laprevotte, E.; Alberici, G.; Bonnefoy, N.; Eliaou, J.F.; Bastid, J. et al. IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci. Rep. 2015, 5, 11874-11884. [CrossRef] [PubMed]
62. Benatar, T.; Cao, M.Y.; Lee, Y.; Lightfoot, J.; Feng, N.; Gu, X.; Lee, V.; Jin, H.; Wang, M.; Wright, J.A. et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol. Immunother. 2010, 59, 805-817. [CrossRef] [PubMed]
63. Benatar, T.; Cao, M.Y.; Lee, Y.; Li, H.; Feng, N.; Gu, X.; Lee, V.; Jin, H.; Wang, M.; Der, S. et al. Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors. Cancer Immunol. Immunother. 2008, 57, 1757-1769. [CrossRef] [PubMed]
64. Duong, M.T.; Akli, S.; Wei, C.; Wingate, H.F.; Liu, W.; Lu, Y.; Yi, M.; Mills, G.B.; Hunt, K.K.; Keyomarsi, K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012, 8, e1002538. [CrossRef] [PubMed]
65. De Marzo, A.M.; Marchi, V.L.; Epstein, J.I.; Nelson, W.G. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am. J. Pathol. 1999, 155, 1985-1992. [CrossRef]
66. You, Z.; Dong, Y.; Kong, X.; Zhang, Y.; Vessella, R.L.; Melamed, J. Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers. Neoplasia 2007, 9, 464-470. [CrossRef] [PubMed]
67. You, Z.; Ge, D.; Liu, S.; Zhang, Q.; Borowsky, A.D.; Melamed, J. Interleukin-17 induces expression of chemokines and cytokines in prostatic epithelial cells but does not stimulate cell growth in vitro. Int. J. Med. Biol. Front. 2012, 18, 629-644. [PubMed]
68. Liu, S.; Zhang, Q.; Chen, C.; Ge, D.; Qu, Y.; Chen, R.; Fan, Y.M.; Li, N.; Tang, W.W.; Zhang, W. et al. Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor. Oncotarget 2016, 7, 13651-13666. [PubMed]
69. Zhang, Q.; Liu, S.; Ge, D.; Zhang, Q.; Xue, Y.; Xiong, Z.; Abdel-Mageed, A.B.; Myers, L.; Hill, S.M.; Rowan, B.G. et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 2012, 72, 2589-2599. [CrossRef] [PubMed]
70. Zhang, Q.; Liu, S.; Parajuli, K.R.; Zhang, W.; Zhang, K.; Mo, Z.; Liu, J.; Chen, Z.; Yang, S.; Wang, A.R. et al. Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition. Oncogene 2016. [CrossRef] [PubMed]
71. Zhou, Y.; Toh, M.L.; Zrioual, S.; Miossec, P. IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine 2007, 38, 157-164. [CrossRef] [PubMed]
72. Bie, Q.; Sun, C.; Gong, A.; Li, C.; Su, Z.; Zheng, D.; Ji, X.; Wu, Y.; Guo, Q.; Wang, S. et al. Non-tumor tissue derived interleukin-17B activates IL-17RB/AKT/β-catenin pathway to enhance the stemness of gastric cancer. Sci. Rep. 2016, 6, 25447-25459. [CrossRef] [PubMed]
73. Li, B.; Shi, X.Y.; Liao, D.X.; Cao, B.R.; Luo, C.H.; Cheng, S.J. Advanced colorectal adenoma related gene expression signature may predict prognostic for colorectal cancer patients with adenoma-carcinoma sequence. Int. J. Clin. Exp. Med. 2015, 8, 4883-4898. [PubMed]
74. Cui, G.; Yuan, A.; Goll, R.; Florholmen, J. IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence. Scand. J. Gastroenterol. 2012, 47, 1304-1312. [CrossRef] [PubMed]
75. Al-Samadi, A.; Moossavi, S.; Salem, A.; Sotoudeh, M.; Tuovinen, S.M.; Konttinen, Y.T.; Salo, T.; Bishehsari, F. Distinctive expression pattern of interleukin-17 cytokine family members in colorectal cancer. Tumour Biol. 2016, 37, 1609-1615. [CrossRef] [PubMed]
76. Housseau, F.; Wu, S.; Wick, E.C.; Fan, H.; Wu, X.; Llosa, N.J.; Smith, K.N.; Tam, A.; Ganguly, S.; Wanyiri, J.W. et al. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res. 2016, 76, 2115-2124. [CrossRef] [PubMed]
77. Pan, B.; Che, D.; Cao, J.; Shen, J.; Jin, S.; Zhou, Y.; Liu, F.; Gu, K.; Man, Y.; Shang, L. et al. Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer. Biomarkers 2015, 20, 232-239. [CrossRef] [PubMed]
78. Pan, B.; Shen, J.; Cao, J.; Zhou, Y.; Shang, L.; Jin, S.; Cao, S.; Che, D.; Liu, F.; Yu, Y. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci. Rep. 2015, 5, 16053-16066. [CrossRef] [PubMed]
79. Numasaki, M.; Watanabe, M.; Suzuki, T.; Takahashi, H.; Nakamura, A.; McAllister, F.; Hishinuma, T.; Goto, J.; Lotze, M.T.; Kolls, J.K. et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 2005, 175, 6177-6189. [CrossRef] [PubMed]
80. He, D.; Li, H.; Yusuf, N.; Elmets, C.A.; Athar, M.; Katiyar, S.K.; Xu, H. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE 2012, 7, e32126. [CrossRef] [PubMed]
81. McAllister, F.; Kolls, J.K. Th17 cytokines in non-melanoma skin cancer. Eur. J. Immunol. 2015, 45, 692-694. [CrossRef] [PubMed]
82. Wu, L.; Chen, X.; Zhao, J.; Martin, B.; Zepp, J.A.; Ko, J.S.; Gu, C.; Cai, G.; Ouyang, W.; Sen, G. et al. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. J. Exp. Med. 2015, 212, 1571-1587. [CrossRef] [PubMed]
83. Wang, L.; Yi, T.; Kortylewski, M.; Pardoll, D.M.; Zeng, D.; Yu, H. IL-17 can promote tumor growth through an IL-6-STAT3 signaling pathway. J. Exp. Med. 2009, 206, 1457-1464. [CrossRef] [PubMed]
84. Doroudchi, M.; Pishe, Z.G.; Malekzadeh, M.; Golmoghaddam, H.; Taghipour, M.; Ghaderi, A. Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac. J. Cancer Prev. 2013, 14, 5225-5230. [CrossRef] [PubMed]
85. Kehlen, A.; Thiele, K.; Riemann, D.; Rainov, N.; Langner, J. Interleukin-17 stimulates the expression of IκB-α mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J. Neuroimmunol. 1999, 101, 1-6. [CrossRef]
86. Wainwright, D.A.; Sengupta, S.; Han, Y.; Ulasov, I.V.; Lesniak, M.S. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS ONE 2010, 5, e15390. [CrossRef] [PubMed]
87. Cantini, G.; Pisati, F.; Mastropietro, A.; Frattini, V.; Iwakura, Y.; Finocchiaro, G.; Pellegatta, S. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol. Immunother. 2011, 60, 1739-1750. [CrossRef] [PubMed]
88. Hu, J.; Ye, H.; Zhang, D.; Liu, W.; Li, M.; Mao, Y.; Lu, Y. U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues. Oncol. Lett. 2013, 6, 993-999. [PubMed]
89. Liang, H.; Yi, L.; Wang, X.; Zhou, C.; Xu, L. Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4+ CD25+ Foxp3+ T cells via releasing transforming growth factor β. Scand. J. Immunol. 2014, 80, 144-150. [CrossRef] [PubMed]
90. Parajuli, P.; Anand, R.; Mandalaparty, C.; Suryadevara, R.; Sriranga, P.U.; Michelhaugh, S.K.; Cazacu, S.; Finniss, S.; Thakur, A.; Lum, L.G. et al. Preferential expression of functional IL-17R in glioma stem cells: Potential role in self-renewal. Oncotarget 2016, 7, 6121-6135. [PubMed]
91. Zhang, J.P.; Yan, J.; Xu, J.; Pang, X.H.; Chen, M.S.; Li, L.; Wu, C.; Li, S.P.; Zheng, L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 2009, 50, 980-989. [CrossRef] [PubMed]
92. Kuang, D.M.; Peng, C.; Zhao, Q.; Wu, Y.; Zhu, L.Y.; Wang, J.; Yin, X.Y.; Li, L.; Zheng, L. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J. Immunol. 2010, 185, 1544-1549. [CrossRef] [PubMed]
93. Sternlicht, M.D.; Lochter, A.; Sympson, C.J.; Huey, B.; Rougier, J.P.; Gray, J.W.; Pinkel, D.; Bissell, M.J.;Werb, Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98, 137-146. [CrossRef]
94. Stallings-Mann, M.L.; Waldmann, J.; Zhang, Y.; Miller, E.; Gauthier, M.L.; Visscher, D.W.; Downey, G.P.; Radisky, E.S.; Fields, A.P.; Radisky, D.C. Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci. Transl. Med. 2012. [CrossRef] [PubMed]
95. Ma, Y.; Aymeric, L.; Locher, C.; Mattarollo, S.R.; Delahaye, N.F.; Pereira, P.; Boucontet, L.; Apetoh, L.; Ghiringhelli, F.; Casares, N. et al. Contribution of IL-17-producing delta T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 2011, 208, 491-503. [CrossRef] [PubMed]
96. O’Sullivan, T.; Saddawi-Konefka, R.; Gross, E.; Tran, M.; Mayfield, S.P.; Ikeda, H.; Bui, J.D. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep. 2014, 7, 989-998. [CrossRef] [PubMed]